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PG (n5 38) OTH (n5 58) P
Number of aphereses; median 2 (1-4) 3 (1-5) 0.12
Group A
(Bortezomib)
Group B
(No Bortezomib)
(range)
Total CD341 cells collected 2.09 1.42 0.003CR1VGPR 12 (31%) 22 (31%)
(x106/kg); median (range)Median PFS (months) 14 23Number of patients collecting 14 (37%) 1 (2%) \0.0001Median OS (months) 80 82
2 million CD341 cells in
one apheresis# clinic visits (MD/PA) 2 (0-6) 1 (0-9) 0.15
# days IV antibiotics 0 (0-7) 0 (0-14) 0.1
# inpatient days 0 (0-4) 0 (0-13) 0.02
# RBC units transfused 0 (0-6) 0 (0-11) 0.22
Platelet units transfused 0 (0-24) 0 (0-36) 0.6
# of CBC/diff performed 7 (3-15) 7 (2-27) 0.26
# of comprehensive metabolic
panels performed
2 (0-6) 2 (0-19) 0.94117
LONG TERM SURVIVAL FOLLOWING HIGH DOSE SEQUENTIAL CHEMO-
THERAPYWITH AUTOLOGOUS HEMATOPOIETIC CELL RESCUE FORMUL-
TIPLE MYELOMA
Doan, P.1, Gasparetto, C.1, Chute, J.1, Horwitz, M.1, Rizzieri, D.1,
Sullivan, K.1, Edwards, J.2, Jacobson, R.3, Corbet, K.1, Chao, N.1,
Long, G.1 1Duke University Medical Center, Durham, NC; 2Florida
Hospital, Orlando, FL; 3Palm Beach Cancer Institute, West Palm Beach,
FL
High-dose therapy (HDT) with autologous hematopoietic cell
rescue (AHCR) improves survival in patients with multiple mye-
loma, but is not curative due to a continuous risk of relapse.
One approach to try to reduce relapse is to optimize pretransplant
therapy and the preparative regimen. We investigated the out-
come of sequential HDT with AHCR. Patients were initially
treated with standard dose chemotherapy (primarily VAD) to
maximum response. They then received cyclophosphamide 4
gm/m2 followed by G-CSF and peripheral blood hematopoietic
cell collection by apheresis upon count recovery. They were
then treated with etoposide 2 gm/m2 followed by G-CSF and
apheresis upon count recovery. The transplant preparative regi-
men consisted of carmustine 500 mg/m2 on day -4 and melphalan
200 mg/m2 on day -2 followed by AHCR on day 0. Seventy-six
patients were treated between 1997 and 2001. The patient popu-
lation included 56% males with a median age at transplant of 54
years (range 39-68 years). Forty patients had IgG myeloma, 11 pa-
tients had IgA myeloma, 8 patients had light chain only disease, 5
patients had nonsecretory disease, 1 patient had IgM myeloma and
subtype is unknown in 11 patients. Forty patients were trans-
planted with CD34 selected cells. The Kaplan-Meir estimated me-
dian progression-free survival is 4.2 years (CI 3.1-6.0 years) with
a median overall survival of 7.2 years (CI 4.8-11.4 years). The me-
dian follow up of the 36 surviving patients is 8.46 years with
a range of 4.71 to 11.4 years. One patient was lost to follow up.
The Kaplan-Meir estimated progression-free survival at 10 years
is 35% with overall survival of 45%. Two patients died of inter-
stitial pneumonitis at 21 and 76 days post transplant and two pa-
tients died of secondary leukemia at 694 and 712 days post
transplant. High dose sequential chemotherapy is well tolerated
and results in long term survival in a significant proportion of pa-
tients with multiple myeloma.118
RETROSPECTIVE COMPARISON OF SECONDARY MOBILIZATION STRATE-
GIES IN CANDIDATES FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANS-
PLANTION WITH A FOCUS ON RESOURCE UTILIZATION:
PLERIXAFOR + G-CSF VERSUS OTHER REGIMENS
Perkins, J., Bookout, R., Sapiro, J., Alsina, M., Ayala, E., Field, T.L.,
Kharfan-Dabaja, M.A., Perez, L.E., Ochoa-Bayona, J.L.,
Tomblyn, M., Daily, K., Elstner, C., Anasetti, C., Fernandez, H.F. Mof-
fitt Cancer Center, Tampa, FL
Successful autologous transplantation relies on hematopoietic cell
mobilization that allows adequate CD34+ cell collection. Depite ap-
propriate mobilization approaches, a significant number of patients
(pts) do not mobilize adequate CD34+ cells and require a second
round of mobilization therapy. We performed a retrospective analy-
sis of our experience with different secondary mobilization strategies
with a focus on resource utilization. Primary endpoint was compar-ing plerixafor versus other regimens with respect to the rate of suc-
cessful second mobilization defined as the ability to collect at least
2106 CD34+ cells/kg (cumulative). Included here are 96 pts receiv-
ing their primary mobilization therapy between 2000-09. Pts are di-
vided into two groups depending on the secondary mobilization
therapy given: Plerixafor + G-CSF (PG; n5 38) or Other (OTH;
n5 58). which included chemotherapy +G-CSF in 15 pts, G-CSF
alone in 23 pts or G-CSF andGM-CSF in 20 pts. There were no dif-
ferences in pt characteristics between the two groups except for
a higher number of non-Hodgkin’s lymphoma pts in the PG group
and more pts with multiple myeloma in the OTH group. In the
PG mobilized group, 29% were first mobilized with chemothera-
py +G-CSF and 71% were mobilized with G-CSF alone. In the
OTH pts, 41% received chemotherapy +G-CSF, 43% G-CSF
alone, and 16% G-CSF +GM-CSF. Median numbers of CD34+
cells (x 106/kg) collected after the first mobilization were 0.39 (0-
1.76) in the PG pts and 0.56 (0-2.08) in the OTH pts. Pts in the
PG group received a median of 2 doses of plerixafor (range 1-4) dur-
ing their second mobilization regimen. Eight of the 38 PG pts were
enrolled on clinical trials requiring at least 2 doses of plerixafor and
a minimum of 2 aphereses. Outcomes following the second mobili-
zation and resource utilization from the first day of second
mobilization to the last day of pheresis are shown below. Thirty-
two of the 38 PG pts (84%) were able to collect a total of at least 2
 106 CD34+ cells/kg from both mobilizations to proceed to trans-
plant; this is compared to 47/58 (80%) in theOTHgroup (p5 0.62).
Of those pts that were transplanted, there were no differences in time
to neutrophil or platelet recovery. The current data suggest that
when using plerixafor plus G-CSF in this setting there is a potential
for significant cost savings based on the reduced apheresis and hos-
pitalization requirements when compared to other forms of mobili-
zation.119
QUALITY OF UMBILICAL CORD BLOODUNITS STORED FOR AUTOLOGOUS
USE AND INFUSED INTRAVENOUSLY IN CHILDREN WITH ACQUIRED
NEUROLOGICAL CONDITIONS
Sun, J., Allison, J., McLaughlin, C., Sledge, L., Waters-Pick, B.,
Kurtzberg, J. Duke University, Durham, NC
Background: Numerous animal models demonstrate neurological
and survival benefits of bone marrow or umbilical cord blood (CB)
infusion in the setting of stroke, thermal injury, ischemia, intracra-
nial hemorrhage and spinal cord injury. Based on these data, we ini-
tiated a pilot study to determine the safety and feasibility of
intravenous (IV) administration of autologous CB (aCB) in young
children with acquired neurological disorders. Most units were elec-
tively stored in private CB banks at the request and expense of the
S202 Poster Session Ichildren’s parents. Unlike public banks, which utilize specific criteria
for banking, private banks generally store any collected unit regard-
less of size or cell content.
Methods: Patients with neurological disorders with banked aCB
were self-referred or referred by their treating physicians. CB
units (CBU) containing .110e7 cells/kg were shipped to Duke
from the banks of origin after confirming identity by HLA typing.
Viability was confirmed on a test sample when available. CBUs,
50% stored in bags and 50% in vials, were thawed and washed
in the standard fashion. Patients were premedicated with Tylenol,
Benadryl and Solumedrol prior to infusion and monitored for
4 hours. Data about patients, infusions and CBUs were collected
retrospectively. Characteristics of CBUs were compared to exist-
ing data from CBUs publicly banked at the Carolinas Cord Blood
Bank.
Results:From3/2004 to 8/2009, 154 childrenwith neurological dis-
orders (78% cerebral palsy, 13% congenital hydrocephalus, 9%
other injuries) received 164 aCB infusions. Median age at infusion
was 2 yrs (range 6 days–9 yrs). One patient had an anaphylactic infu-
sion reaction which responded to medical therapy and stopping the
infusion. Mean pre-cryopreservation volume (66.2 vs 97.6 ml,
p\0.001), TNC (12.3 vs 15.510e8, p\0.001), and CD34 (3.0
vs 4.110e6, p5 0.004) were significantly lower than publicly stored
CBUs. Post thaw sterility cultures were positive in 6.5% of CBUs in-
fused versus 0.5% of publicly stored units. Post thaw recoveries of
TNC, 3.310e8 (27% pre-cryo TNC), and CD34, 1.2 (40% pre-
cryo CD34), were also lower than expected.
Conclusions: IV infusion of aCB is safe and feasible in young chil-
dren with neurological conditions. The overall quality parameters of
privately banked UCBs was inferior to those stored in public banks.
If evidence for efficacy of aCB is established clinically, the quality of
aCB units should be held to the same standards as those stored in
public banks.120
TREATMENT WITH HYPER-CVAD RESULTS IN POOR MOBILIZATION OF
PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH MANTLE CELL
LYMPHOMA
Hill, B.T.1, Rybicki, L.A.2, Smith, S.1, Dean, R.1, Kalaycio, M.1,
Pohlman, B.1, Sweetenham, J.W.1, Tench, S.1, Sobecks, R.1,
Andresen, S.1, Copelan, E.1, Bolwell, B.J.1 1Cleveland Clinic, OH;
2Cleveland Clinic, OH
Background: Hyper-CVAD (fractionated cyclophosphamide, vin-
cristine, doxorubicin and dexamethasone combined with high
doses of cytarabine and methotrexate) is an intense chemotherapy
regimen frequently used as front line therapy for a number of he-
matologic malignancies including mantle cell lymphoma. It has
been observed anecdotally that patients with mantle cell lym-
phoma who have been treated with hyper-CVAD have more dif-
ficulty mobilizing sufficient PBSC than those who have been
treated with alternative regimens.
Patients and Methods: To address this question, we retrospec-
tively analyzed mobilization data from 74 consecutive patients
over the age of 18 diagnosed with mantle cell lymphoma who un-
derwent ASCT at the Cleveland Clinic between July, 1996 and
November, 2008. 26 of these patients had previously been treated
with hyper-CVAD and 48 had received alternative regimens (pre-
dominantly CHOP with or without rituximab). Patients treated
with hyper-CVAD were more likely to have undergone mobiliza-
tion with VP16 +G-CSF (VP-G): 92% received VP-G, whereas
only 50% of patients treated with alternative regimens received
VP-G (P5\ 0.001).
Results: Patients treated with hyper-CVAD collected fewer CD34+
stem cells on day 1 (median5 0.43 106 CD34+ cells/kg) compared
to patients treated with alternative regimens (median5 3.00  106,
P5 0.002, see Table). In addition, patients treated with hyper-
CVAD were also more likely to fail in collecting sufficient CD34+
cells during their first mobilization attempt compared to patients
treated with alternative regimens 23.1% vs. 4.2%, P5 0.012). Pa-tients treated with hyper-CVAD underwent a median total of 5
days of pheresis vs. 3 days for patients treated with alternative regi-
mens (P5 0.019).
Conclusions: Compared to patients treated with alternative regi-
mens, patients with mantle cell lymphoma treated with hyper-
CVAD were more likely to undergo mobilization with a VP16-con-
taining regimen yet still collected fewer CD34+ cells (day 1, day 2,
days 1 + 2, and total), required more total days of pheresis, and
more frequently required a second mobilization attempt. These re-
sults suggest a potential role of alternative mobilizing strategies in
patients with mantle cell lymphoma as an adjuvant to standard prim-
ing regimens in order to improve mobilization of PBSC prior to
ASCT.
Table. Mobilization Results
Hyper-CVAD (N5 26) Alternative Regimens (N5 48)CharacteristicMedian
(range) (Number
percent)Median
(range)Number
(percent) PCD341 cells
collected on
day 1 (x 106/kg)0.43
(0.09-13.33)3.00
(0.02-60.36)0.002CD341 cells
collected on day
2 (x 106/kg)0.62
(0.09-12.88)2.65
(0.11-29.16)0.008Total CD341 cells
collected
(x 106/kg)4.13
(2.11-27.88)8.92
(2.06-89.52)0.037Total days of
pheresis5 (2-11) 3 (2-10) 0.019Number of
patients who
failed to collect
sufficient CD341
cells during first
mobilization
attempt6 (23.1%) 2 (4.2%) 0.012121
CYCLOPHOSPHAMIDE OR PLERIXAFOR AND G-CSF STEM CELL MOBILI-
ZATION (SCM): INITIAL COST COMPARISON ANALYSIS
Jagasia,M.H.1, Pickard, S.2, Chen, H.3, Dixon, S.4, Savani, B.N.5 1Van-
derbilt University Medical Center, Nashville, TN; 2University of Illinois,
Chicago, IL; 3Vanderbilt University Medical Center, Nashville, TN
Objectives: Autologous SCM is usually done using myelosuppres-
sive chemotherapy plus G-CSF (G), which is considered safe and ef-
fective, but exposes patients (pts) to risks and side effects. To better
understand the comparative effectiveness of standard and newer
treatments for SCM, the aims of study were: (1) clinical outcomes
and cost consequences of cyclophophamide (CY) plus G SCM (2)
to compare outcomes of CY +G to a clinical trial of plerixafor
(P)+G.
Methods: A retrospective study was conducted in all patients un-
dergoing first SCM from 1/04 to 3/08 (N5 241) with CY (3
gm/m2) and G (10 mcg/kg started day after CY for 10 days with
a planned first day of collection on day 11) and pheresis initiated
when peripheral blood had .15 CD34+ cells/uL. Positive clinical
outcome (PCO) was defined as .2106 CD34+ cells/kg collected
on planned day of collection in 1 or 2 apheresis without a prior
negative event that led to additional clinic/inpatient evaluation.
The cost of drugs, pheresis, product processing, and clinical events,
were reported based on Medicare part B physician, laboratory, and
ancillary fee schedule. Data on pts undergoing SCM with P +G
were obtained from a published clinical trial in pts with myeloma
